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Chemical genetic identification of CDKL5 substrates
reveals its role in neuronal microtubule dynamics
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Alysson R Muotri2,5,* & Sila K Ultanir1,**
Abstract
Loss-of-function mutations in CDKL5 kinase cause severe neurode-
velopmental delay and early-onset seizures. Identification of CDKL5
substrates is key to understanding its function. Using chemical
genetics, we found that CDKL5 phosphorylates three microtubule-
associated proteins: MAP1S, EB2 and ARHGEF2, and determined
the phosphorylation sites. Substrate phosphorylations are greatly
reduced in CDKL5 knockout mice, verifying these as physiological
substrates. In CDKL5 knockout mouse neurons, dendritic micro-
tubules have longer EB3-labelled plus-end growth duration and
these altered dynamics are rescued by reduction of MAP1S levels
through shRNA expression, indicating that CDKL5 regulates micro-
tubule dynamics via phosphorylation of MAP1S. We show that
phosphorylation by CDKL5 is required for MAP1S dissociation from
microtubules. Additionally, anterograde cargo trafficking is
compromised in CDKL5 knockout mouse dendrites. Finally, EB2
phosphorylation is reduced in patient-derived human neurons. Our
results reveal a novel activity-dependent molecular pathway in
dendritic microtubule regulation and suggest a pathological mech-
anism which may contribute to CDKL5 deficiency disorder.
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Introduction
Cyclin-dependent kinase-like 5 (CDKL5) is an X-linked gene
encoding a 115 kDa serine/threonine kinase, a member of the
CMGC (CDK, MAPK, GSK3 and CLK containing) kinase family
(Manning et al, 2002). Mutations in a single copy of the CDKL5
gene cause a rare neurodevelopmental disorder predominantly
observed in girls (Kalscheuer et al, 2003; Tao et al, 2004; Weaving
et al, 2004; Scala et al, 2005). Although initially categorized as an
atypical Rett syndrome, CDKL5 deficiency is now considered a
distinct disorder, named CDKL5 deficiency disorder (CDD). CDD is
characterized by early-onset seizures and widespread neurodevel-
opmental delay (Bahi-Buisson & Bienvenu, 2012; Fehr et al, 2013).
Pathological deletions and nonsense mutations are found through-
out the CDKL5 gene, whereas disease-causing missense variants
are highly enriched in the N-terminal kinase domain of CDKL5,
highlighting the importance of its kinase activity (Fehr et al,
2016).
In mice, CDKL5 is expressed throughout the brain starting at
late embryonic stages and through adulthood, indicating a role in
postnatal development and function in the nervous system (Chen
et al, 2010; Hector et al, 2016, 2017). CDKL5 mRNA is highly
enriched in foetal and adult human brains (Hector et al, 2016).
CDKL5’s functions in excitatory and inhibitory synaptic transmis-
sion as well as dendrite, axon and spine development were stud-
ied using shRNA-mediated knockdown or CDKL5 knockout mice
(Baltussen et al, 2017; Zhou et al, 2017). In addition, patient-
derived induced pluripotent stem cells (hiPSCs) were used to
obtain postmitotic neurons from patients with CDKL5 mutations
(Amenduni et al, 2011; Ricciardi et al, 2012). However, no clear
consensus has emerged on the cellular and molecular functions of
CDKL5. Specifically, its direct physiological substrates are
unknown.
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The microtubule cytoskeleton is required for fundamental cellu-
lar processes such as long-range intracellular transport and for
dynamic cellular changes such as neural migration or neurite forma-
tion (Conde & Caceres, 2009; Kapitein & Hoogenraad, 2015). Micro-
tubules in dendrites are oriented in mixed polarity (Baas et al,
1988). Microtubule plus-end growth visualized by fluorescently
tagged end-binding proteins in living neurons helped characterize
microtubule dynamics in dendrites (Stepanova et al, 2003; van de
Willige et al, 2016; Yau et al, 2016). In primary neurons, dendritic
neuronal activity and synaptic plasticity manipulations alter micro-
tubule dynamics (Hu et al, 2008; Jaworski et al, 2009; Kapitein
et al, 2011; Merriam et al, 2011; Ghiretti et al, 2016). Microtubule
architecture and dynamics influence cargo trafficking on dendrites
and axons (Yogev et al, 2016; Tas et al, 2017). Microtubules play
central roles during neuronal development and function, and
however, signalling pathways that regulate microtubule architec-
ture, dynamics and microtubule-dependent trafficking remain to be
elucidated.
In this study, we identify CDKL5’s direct substrates in mouse
brain using a chemical genetic method (Hertz et al, 2010; Ultanir
et al, 2012, 2014). We find that CDKL5 phosphorylates three micro-
tubule-binding proteins, Rho guanine nucleotide exchange factor 2
(ARHGEF2), microtubule-associated protein 1S (MAP1S) and micro-
tubule-associated protein RP/EB family member 2 (MAPRE2/EB2),
implicating CDKL5 in microtubule-dependent processes. We show
that EB2 Ser222 and MAP1S Ser812 phosphorylations are dramati-
cally reduced in the CDKL5 knockout mouse brain, making them
bona fide phosphorylation sites for CDKL5. EB2 phosphorylation is
detected predominantly in dendrites of excitatory neurons. By imag-
ing dendritic microtubule dynamics using EB3-tdTomato, we show
that CDKL5 KO neurons have enhanced duration of plus-end
growth, an effect that is dependent on MAP1S’s direct binding to
microtubules. We find specific defects in anterograde cargo traf-
ficking of TrkB puncta. Interestingly, novel substrate phosphoryla-
tion is also highly reduced in patient iPSC-derived neurons,
indicating that these substrates are conserved and are affected in
human patients. Finally, we provide evidence that CDKL5-depen-
dent phosphorylations are NMDAR activity dependent, suggesting a
role in activity-dependent circuit formation. Our findings describe a
novel regulatory mechanism on microtubules that is compromised
in CDKL5 deficiency disorder.
Results
Chemical genetic identification of CDKL5 substrates MAP1S, EB2
and ARHGEF2
We used a chemical genetic approach to determine CDKL5’s
substrates in mouse brain lysates (Fig 1A; Blethrow et al, 2004;
Hertz et al, 2010). This method utilizes analog-specific (AS) kinases,
which can accept bulky ATP analogs owing to their enlarged ATP
binding pocket. The gamma phosphate in bulky ATP analogs is
replaced with a thiophosphate allowing the AS-kinase to thiophos-
phorylate its substrates. Bio-orthogonal bulky ATPcS analogs cannot
be effectively used by wild-type kinases present in biological
samples, allowing thiophosphorylation and labelling to be specific
for the AS-kinase. First, to obtain an enlarged ATP binding pocket,
we mutated the gatekeeper residue Phenylalanine 89 to a smaller
amino acid Alanine (F89A) in CDKL5 kinase domain (amino acids
1–352; Appendix Fig S1A; Shah et al, 1997). Next, we tested the
mutation’s effect on CDKL5’s autophosphorylation activity using a
non-radioactive kinase assay utilizing ATPcS and its analog benzyl-
ATPcS. Thiophosphate is reacted with p-nitro-benzyl-mesylate to
obtain an epitope that is detected by a thiophosphate ester antibody
(Allen et al, 2007). We found that F89A mutation enabled CDKL5 to
utilize benzyl-ATPcS, albeit at low levels (Fig 1B and C). We engi-
neered a second-site suppressor mutation C152A, which had been
used to rescue NDR1 kinase (Ultanir et al, 2012; Appendix Fig S1B),
and found that CDKL5 F89A/C152A activity with benzyl-ATPcS was
comparable to wild-type kinase activity utilizing ATPcS (Fig 1B and
C). CDKL51–352 F89A/C152A double mutant (from here onwards
referred to as AS-CDKL5) could also thiophosphorylate Amphi-
physin-1 (AMPH1), confirming its activity towards a known in vitro
substrate (Sekiguchi et al, 2013; Appendix Fig S1C). We purified
AS-CDKL5 either from HEK293 cells or from insect cells.
In order to label CDKL5 substrates, we reacted purified AS-
CDKL5 and benzyl-ATPcS with 1–2 mg of postnatal day 12 (P12)
mouse brain lysate. Thiophosphorylated substrate proteins were
digested to peptide fragments, and thiophosphopeptides were puri-
fied and identified using mass spectrometry (Fig 1A). We used
kinase-dead (KD) CDKL5 (K42A) as negative control and conducted
three independent experiments totalling eight AS replicates. We
repeatedly detected ARHGEF2 Ser122, EB2 Ser222 and MAP1S
▸Figure 1. Identification of CDKL5 substrates using chemical genetics.A Schematic of chemical genetic kinase substrate identification method. AS-CDKL5 utilizes benzyl-ATPcS to thiophosphorylate its substrates. Following trypsin digest,
thiol-containing peptides are captured on iodoacetyl agarose beads. Thiophosphate ester linked peptides are released by oxone induced hydrolysis while cysteine-
containing peptides remain attached. Eluted phosphopeptides are analysed with liquid chromatography-tandem mass spectrometry (LC-MS/MS).
B, C CDKL51–352 autophosphorylation is shown. WT CDKL5 uses ATPcS, KD is inactive, F89A uses benzyl-ATPcS with reduced efficiency, F89A/C152A mutant has rescued
activity. Quantification of Thio-P signal is normalized for CDKL5 levels (HA), and KD background is subtracted. Fisher’s LSD: n = 4 replicates. bn, benzyl.
D A list of novel CDKL5 substrate targets and phosphorylation sites identified. All phosphorylation sites are conserved in human. # MAP1S pS812 is identified based
on sequence homology. Red = phosphorylated serine, bold = RPXS consensus sequence.
E–H In vitro kinase assays showing efficient MAP1S phosphorylation by CDKL5. 50 ng (40 nM) AS-CDKL5 phosphorylates 150 ng (50 nM) MAP1S very rapidly (E, F). In
30 min of incubation, 150 ng MAP1S is phosphorylated by small amounts of CDKL5 (G, H). Quantification of phosphorylated MAP1S is normalized to maximum
intensity. n = 2 replicates.
I–L Western blots of in vitro kinase assays showing loss of phosphorylation in phosphomutants ARHGEF2 S122A (I), EB2 S222A (J) and MAP1S S786/812A (K). Substrate
levels are shown by Coomassie staining underneath. MAP1S phosphorylation is quantified in (L). Dunnett’s multiple comparison: n = 3 replicates.
Data information: Thio-P, anti-thiophosphate ester antibody; n.s., not significant, *P < 0.05, ***P < 0.001, ****P < 0.0001, error bars are SEM. In panel (K), non-relevant
lanes have been removed for simplicity (see accompanying Source Data for full blot).
Source data are available online for this figure.
2 of 18 The EMBO Journal 37: e99763 | 2018 ª 2018 The Francis Crick Institute
The EMBO Journal CDKL5 as a microtubule regulator Lucas L Baltussen et al
Ser786 phosphopeptides specifically in AS-kinase samples and not
in negative controls (Fig EV1, Appendix Figs S2 and S3). All phos-
phorylation sites contained an RPXS* consensus motif, where X is
any amino acid and S* is the phosphorylated residue (Fig 1D). To
validate these putative substrates, we performed in vitro kinase
assays using purified AS-CDKL5 and purified substrates. We found
that all three substrates are highly efficiently phosphorylated by
CDKL5 in a time-dependent (Fig 1E and F, and Appendix Fig S4)
and CDKL5 concentration-dependent manner (Fig 1G and H, and
Appendix Fig S4). Next, to confirm the identified phosphorylation
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sites, we generated phosphomutant substrates by mutating the Seri-
nes to Alanines and performed in vitro kinase assays. We found that
ARHGEF2 S122A (Fig 1I) and EB2 S222A (Fig 1J) are not phospho-
rylated by CDKL5, confirming the mutated Serines as the sole phos-
phorylation sites on these substrates. In contrast, full-length MAP1S
phosphorylation was reduced in MAP1S S786A mutant but not
completely eliminated. Upon inspection of MAP1S protein sequence,
we determined another putative phosphorylation site with the same
RPXS consensus motif at Ser812. MAP1S phosphorylation was lost
in double phosphomutant S786/812A, indicating that CDKL5 can
phosphorylate MAP1S on both sites (Fig 1K and L). In summary,
our chemical genetic screen identified three novel CDKL5 substrates
on which four phosphorylation sites containing RPXS* motif were
confirmed (Fig 1D). Interestingly, all substrates are microtubule-
associated proteins, suggesting a role for CDKL5 in microtubule
regulation.
MAP1S and EB2 are physiological substrates of CDKL5 in brain
In order to study the phosphorylation events more closely, we
generated rabbit polyclonal phosphospecific antibodies targeting
the four mouse phosphorylation sites that we identified (Fig 1D).
We expressed wild-type (WT) and phosphomutant substrates,
ARHGEF2, EB2 and MAP1S, together with full-length wild-type or
kinase-dead CDKL5 in HEK293 cells. We found that ARHGEF2
Ser122 and MAP1S Ser786 phosphorylation levels were increased
with CDKL5 overexpression, demonstrating that these substrates
can be phosphorylated by CDKL5 in cells, while EB2 Ser222 and
MAP1S Ser812 sites were already highly phosphorylated endoge-
nously (Fig EV2A–C). Importantly, for all four cases, phosphos-
pecific antibodies recognized the WT but not the phosphomutant
substrates, indicating their specificity for phosphorylated
substrates.
Using these antibodies, we tested if the novel substrates are
phosphorylated by CDKL5 in vivo in mice. CDKL5 protein was
shown to be expressed in the cortex of wild-type (WT) mice and
completely lost in CDKL5 knockout (KO) mice (Fig 2A). We
found that endogenous EB2 Ser222 (pS222) and MAP1S Ser812
(pS812) phosphorylations are dramatically reduced in CDKL5
knockout mice cortex at P20 (Fig 2A and B). ARHGEF2 Ser122
and MAP1S Ser786 phosphospecific antibodies did not detect any
specific signal, possibly due to insufficient sensitivity of these
antibodies. These data indicated MAP1S and EB2 to be physiolog-
ical substrates of CDKL5.
We also investigated the temporal and spatial distribution of
CDKL5 activity. For this purpose, we examined the developmental
time course of CDKL5 expression and of EB2 and MAP1S phospho-
rylation in mouse cortex. When comparing WT and KO cortical
lysates from P4, P12, P20 and P50, we found that at all ages EB2
pS222 and MAP1S pS812 are highly dependent on CDKL5, as shown
by absence of phosphorylations in CDKL5 KO (Figs 2C and D, and
EV2D and E for full molecular range). Interestingly, while CDKL5
protein level increased postnatally and remained at its highest level
in adult, CDKL5 activity towards EB2 pS222 and MAP1S pS812 was
reduced significantly through 2nd to 3rd postnatal weeks. In order to
assay phosphatase regulation of these substrates, we treated
cultured neurons at younger (DIV11) or older (DIV22) developmen-
tal stages with PP1/PP2A type phosphatase inhibitor, okadaic acid
(OA). We found that OA increased EB2 pS222 levels in both stages
(Fig EV3A). The fold increase in EB2 pS222 was larger at DIV22
when compared to DIV11, indicating that PP1/PP2A activity may be
higher in older stages than in younger neurons (Fig EV3B).
However, even in the presence of OA the observed decrease in EB2
phosphorylation in older neurons remained, indicating that addi-
tional factors likely contribute to observed reduction in EB2 pS222
(Fig EV3C).
Next, we examined the cell-type specificity of CDKL5 activity
by deleting CDKL5 in excitatory neurons using Nex-Cre mice
(Goebbels et al, 2006) crossed with floxed CDKL5 mouse (Amen-
dola et al, 2014). We observed that the vast majority of CDKL5 is
found in excitatory neurons and that EB2 Ser222 and MAP1S
Ser812 phosphorylations are significantly reduced at P8 in cortex
of excitatory neuron-specific CDKL5 conditional knockouts (Fig 2E
and F). In order to determine the subcellular distribution of phos-
phorylated CDKL5 substrates, we immunostained dissociated
cortical neuron cultures with EB2 pS222. We found that total EB2
and EB2 pS222 were largely present in dendrites and EB2 pS222
staining was absent in CDKL5 KO cultures confirming its speci-
ficity (Fig 2G). In order to assess the specificity of EB2 pS222
staining, we knocked down endogenous EB2 using a previously
reported shRNA sequence (Komarova et al, 2005). In contrast to
scrambled shRNA control, EB2 shRNA caused a dramatic reduc-
tion in total EB2 and pS222 in dendrites of neurons expressing
these plasmids along with GFP (Fig EV2F). Nuclear staining
present with pS222 was non-specific background, as it was
observed with total EB2 staining and it was not reduced by EB2
shRNA. These findings indicated that CDKL5 phosphorylates EB2
and MAP1S in vivo during early postnatal development and that
▸Figure 2. MAP1S and EB2 are physiological substrates of CDKL5 in mammalian brain.A, B In vivo substrate phosphorylations are assessed by Western blotting of 5 WT (CDKL5+/Y) and 5 CDKL5 KO (CDKL5/Y) mouse cortical lysates using phosphospecific
antibodies. EB2 pS222 and MAP1S pS812 are dramatically reduced in KOs. Quantification of substrate phosphorylation is normalized for total protein level.
Student’s t-test: n = 5 animals per genotype.
C, D Developmental expression of CDKL5 and levels of its substrate phosphorylations in P4–P50 cortex. CDKL5-dependent substrate phosphorylation is quantified by
subtracting KO from WT levels for each age. n = 3 animals per age per genotype.
E, F Expression of CDKL5 and levels of substrate phosphorylation in P8 Nex-Cre conditional KO cortex. CDKL5 protein expression is almost completely lost.
Quantification of substrate phosphorylation is normalized for total protein level. Student’s t-test: n = 3 animals per genotype.
G CDKL5 WT and CDKL5 KO neurons in culture are co-stained with neuronal dendrite marker MAP2, EB2 and EB2 pS222. EB2 pS222 is lost in CDKL5 KO dendrites.
Scale bar is 20 lm.
Data information: EB2 isoform 1/2 (37 kD) is quantified. ****P < 0.0001, error bars are SEM.
Source data are available online for this figure.
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CDKL5 is highly active in dendrites of pyramidal neurons in the
cortex.
EB2 Ser222 phosphorylation is suppressed by NMDA
receptor activity
Neuronal activity and NMDA receptors are crucial in sculpting
developing neuronal circuits and for activity-dependent plasticity in
adults (Wong & Ghosh, 2002). We next tested if CDKL5 substrate
phosphorylation was affected by NMDAR-dependent neuronal activ-
ity. We treated cortical neuronal cultures with 50 mM KCl for vary-
ing durations to induce neuronal depolarization. We found that
phosphorylation of EB2 Ser222 was reduced to 50% of its initial
levels within 10 min of KCl treatment (Fig 3A and B). This effect
was due to depolarization and not because of altered osmolarity
(Appendix Fig S3C). Total CDKL5 levels were also reduced by 25%
(Fig 3C). To test the role of NMDAR on EB2 pS222 regulation, we
inhibited NMDAR with 100 lM AP5 during KCl treatment and found
that AP5 largely rescued the KCl-mediated EB2 pS222 reduction
(Fig 3A and B). Finally, we applied NMDA on cultured neurons and
found that NMDA application reduced EB2 phosphorylation,
supporting NMDAR-dependent regulation of CDKL5 substrate phos-
phorylation (Fig 3D and E). These data showed that CDKL5’s phos-
phorylation of EB2 is inhibited by NMDAR activity, suggesting that
CDKL5 contributes to activity-dependent circuit formation.
CDKL5 loss leads to reduced microtubule dynamics via MAP1S
We reasoned that since CDKL5 phosphorylates microtubule-bind-
ing proteins, its loss could lead to disruption of neuronal
0 20 40 60
0
50
100
Time (min)
To
ta
lC
D
K
L5
(%
)
***
0 20 40 60
0
50
100
Time (min)p
S
22
2
/t
ot
al
E
B
2
(%
)
*****
*
A
100 kD
37 kD
37 kD
100 kD
37 kD
50 kD
37 kD
50 kD
CDKL5
min
50 mM KCl
0 5 10 20 40 60
EB2 pS222
EB2 total
CDKL5
min
EB2 pS222
EB2 total
Tubulin
Tubulin
0 1 2 5 10 20
50 µM NMDA
100 µM AP5 + 50 mM KCl
0 5 10 20 40 60
B
D E
C
50 mM KCl 100 µM AP5 + 50 mM KCl
pS222 / total EB2
Total CDKL5
0 5 10 15 20
0
50
100
150
Time (min)
In
te
ns
ity
 (
%
)
***
*
Figure 3. Phosphorylation of EB2 Ser222 is suppressed by NMDAR activity.
A–C Protein lysates were obtained from cortical neuronal cultures treated with 50 mM KCl applied directly to culture media for indicated durations. 100 lm AP5 was
used to block NMDAR activity during KCl treatment. Quantification of phosphorylated EB2 (B) and total CDKL5 (C) is normalized to 0 min time point. EB2
phosphorylation is significantly decreased after 10 min of KCl treatment compared to 0 min. CDKL5 protein levels are slightly reduced after 40 min compared to
0 min. Dunnett’s multiple comparison: n = 3 replicates.
D, E Protein lysates were obtained from cortical neuronal cultures treated with 50 lM NMDA applied directly to culture media for indicated durations. Quantification of
phosphorylated EB2 and total CDKL5 is normalized to 0 min time point. EB2 S222 phosphorylation is significantly reduced after 10 min compared to 0 min.
Dunnett’s multiple comparison: n = 3 replicates.
Data information: *P < 0.05, **P < 0.01, ***P < 0.001, error bars are SEM.
Source data are available online for this figure.
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morphology. We tested this by examining CDKL5 KO mice in
neuronal cultures and in vivo. In CDKL5 KO cortical primary
neurons, we found a slight (10%) reduction in total dendrite
length in cortical but not hippocampal cultures at 11 days in vitro
(DIV; Fig EV4A–C). However, there was no significant alteration
in basal dendrites of Thy1-YFP-expressing Layer V pyramidal
neurons (Feng et al, 2000) in CDKL5 KO mice at P20 (Fig EV4D–
F). In addition, axonal growth was not affected in CDKL5 KO
neurons at DIV4 (Fig EV4G and H). These findings indicated that
no major disruptions are present in dendrites of CDKL5 KO pyra-
midal neurons. While these results and others in literature (Zhou
et al, 2017) did not provide compelling evidence for robust effects
of CDKL5 on neuronal morphology, it prompted us to examine
dendritic microtubules more closely.
Both EB2 and MAP1S are ubiquitously expressed in mamma-
lian tissues and are implicated in regulating microtubule dynamics
(Goldspink et al, 2013; Tegha-Dunghu et al, 2014). Given the
predominant localization of EB2 pS222 on excitatory neuron
dendrites, we decided to examine neuronal microtubule dynamics
in cultured cortical neuron dendrites. For this purpose, we imaged
tdTomato-tagged EB3 in cortical neuron dendrites in dissociated
cultures (Fig 4A, Movies EV1 and EV2). Cortical neuronal cultures
were prepared from WT and CDKL5 KO littermates, transfected
with EB3-tdTomato and live-imaged at DIV14. In agreement with
previous reports (Stepanova et al, 2003; Ghiretti et al, 2016), we
observed both anterograde (75%) and retrograde (25%) EB3
comets in dendrites, with no difference in their ratio between WT
and CDKL5 KO (Fig EV5A). However, we found a robust increase
in comet distance (2.06 lm in WT to 3.05 lm in CDKL5 KO) and
comet lifetime (10.1 s in WT to 15 s in CDKL5 KO; Fig 4B and C)
with no difference in comet velocity (Fig 4D). Results were simi-
lar when anterograde and retrograde comets were analysed sepa-
rately (Fig EV5B). Next, we asked if EB2 or MAP1S could mediate
CDKL5’s effect on microtubule dynamics. We designed MAP1S
shRNAs and used a known EB2 shRNA sequence (Komarova
et al, 2005) to knock down these substrates in CDKL5 WT and
KO cortical neurons (Fig EV5D). Both MAP1S shRNAs caused a
significant decrease in comet lifetime in WT cortical neurons
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Figure 4. Microtubule dynamics are reduced in CDKL5 KO dendrites via MAP1S.
A Representative kymographs of EB3-tdTomato in cortical neuron dendrites at DIV14.
B–D In CDKL5 KOs (CDKL5/Y), comet distance (B) and lifetime (C) are increased when compared to WT (CDKL5+/Y). Comet velocity (D) is unchanged. Student’s t-test:
n = 16/615 and 15/381 neurons/comets in WT and KO, respectively.
E Representative kymographs of CDKL5 WT and KO neurons transfected with control shRNA and MAP1S shRNA.
F Comet lifetime is higher in control shRNA expressing KOs than WTs. MAP1S shRNA expression reduces comet lifetime in KO neurons. EB2 shRNA-mediated
knockdown does not alter microtubule dynamics in WT or KO. Tukey’s multiple comparison: n = 12–15 neurons, 388–741 comets per condition.
Data information: n.s., not significant, **P < 0.01, ****P < 0.0001, error bars are SEM.
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(Fig EV5E) but no significant changes in comet direction, density
or velocity (Fig EV5F–H). Interestingly, MAP1S knockdown
rescued the increase in comet lifetime in CDKL5 KO neurons,
while EB2 knockdown had no effect (Fig 4E and F). These data
indicated that CDKL5 positively regulates plus-end dynamic insta-
bility by phosphorylating MAP1S, causing shorter periods of plus-
end growth.
CDKL5 is necessary for efficient anterograde trafficking
along dendrites
Microtubule plus tip dynamics and microtubule stability affect cargo
trafficking along neuronal dendrites (Tas et al, 2017). Microtubule-
based trafficking of cargo such as TrkB is important for neuronal
function (Zweifel et al, 2005), and in dendrites, it is dependent on
minus-end directed dynein and plus-end directed kinesin (Hirokawa
et al, 2010; Ayloo et al, 2017). Therefore, we decided to analyse
dendritic transport of BDNF/TrkB, a well-studied cargo for
microtubule-based transport, and tested if trafficking of BDNF/TrkB
carrying endosomal vesicles was affected in CDKL5 KO neurons. In
TrkB-RFP-transfected cortical neuron dendrites, we could observe
numerous TrkB-RFP endosomes moving in both anterograde and
retrograde directions, as previously described (Ghiretti et al, 2016;
Fig 5A, Movies EV3 and EV4). We analysed these using a particle
tracking algorithm (Fig 5B, Movies EV5 and EV6). In CDKL5 KO
neurons, we found no difference in the fraction of stationary
TrkB-RFP puncta (Fig 5C), the ratio of anterograde/retrograde runs
(Fig 5D) or the velocity of the puncta, which was comparable to
previous reports (Fig 5E). Interestingly, we observed a significant
reduction in run lengths of anterograde TrkB puncta in CDKL5 KO
dendrites (Fig 5F). These data showed that in CDKL5 deficiency
anterograde cargo transport is compromised.
CDKL5’s phosphorylation of MAP1S light chain inhibits its
microtubule binding
The finding that loss of MAP1S phosphorylation in CDKL5 KO
neurons is rescued by MAP1S knockdown raised the possibility that
CDKL5 negatively regulates MAP1S function. MAP1S is a member of
MAP1 family of microtubule-associated proteins, which are prote-
olytically cleaved into heavy and light fragments that form a
complex on microtubules. Ser786 and Ser812 phosphorylation sites
are found on MAP1S light chain’s (LC) microtubule-binding domain
(Orban-Nemeth et al, 2005; Fig 6A). We tested if phosphorylation of
these sites alters microtubule-binding affinity of MAP1S LC by over-
expressing WT or kinase-dead CDKL5 with WT or S786/812A phos-
phomutant MAP1S in COS-7 cells. We found that MAP1S LC’s
robust localization to microtubules is strongly disrupted upon
CDKL5 WT expression and this effect is dependent on the phospho-
rylation sites (Fig 6B–D). Furthermore, microtubule co-sedimenta-
tion assay showed that purified MAP1S LC binds polymerized
microtubules (pellet) and that pre-phosphorylation of MAP1S LC
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Figure 5. TrkB trafficking is impaired in CDKL5 KO dendrites.
A, B Representative stills (A) and kymographs (B) of TrkB-RFP overexpressed in dendrites of WT and CDKL5 KO DIV14 cortical neurons. Scale bar is 5 lm.
C, D No significant change is observed in the ratio of dynamic vs. stationary vesicles (C) or anterograde vs. retrograde runs (D). S, stationary; D, dynamic; A, anterograde;
R, retrograde. Vesicles with a net distance > 5 lm were considered dynamic.
E, F Both anterograde and retrograde runs show a trend towards reduced velocity in CDKL5 KO neurons (E). Anterograde run lengths are significantly reduced in KO
compared to WT neurons (F).
Data information: Student’s t-test: n = 4 cells/121–138 runs per condition. n.s., not significant, *P < 0.05, error bars are SEM.
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with CDKL5 highly increased soluble MAP1S (supernatant; Fig 6E
and F). MAP1S LC phosphorylation is likely to be saturated as
pS786 and pS812 antibodies were not enriched in the soluble
fraction (Appendix Fig S5A and B). In vitro MAP1S LC microtubule-
binding affinity is therefore also dependent on other factors such as
MAP1S LC:Tubulin ratio. A putative phosphomimetic MAP1S LC
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Figure 6. MAP1S phosphorylation by CDKL5 impairs its microtubule binding.
A Schematic representation of MAP1S protein domains. Phosphorylation sites S786 and S812 (green Ps) are on the microtubule-binding domain of MAP1S LC. Scissors
indicate proteolytic cleavage.
B COS-7 cells expressing HA-MAP1S LC, Flag-CDKL5 WT/kinase-dead (KD) is shown with endogenous a-tubulin staining. MAP1S does not localize to microtubules
when phosphorylated by CDKL5. Scale bar is 20 lm.
C, D The percentage of cells where a-tubulin and MAP1S LC are colocalized (C) and the quantification of MAP1S LC and a-tubulin colocalization by Pearson correlation
coefficient (D). Tukey’s multiple comparison: n = 22–24 cells per condition.
E, F Taxol-stabilized microtubule co-sedimentation assay shows direct binding of MAP1S LC to microtubules is reduced upon prior phosphorylation by CDKL5.
Quantification of soluble MAP1S in the supernatant (s/n) fraction is normalized to the MT-bound pellet fraction. 3:1 MT:MAP1S LC ratio used here. Tukey’s multiple
comparison: n = 3 technical repeats.
G HA-MAP1S LC is overexpressed and stained with anti-HA antibody in cultured cortical neurons (red). Numerous loops at the dendrites’ tips are observed
(arrowheads). Scale bar is 5 lm.
Data information: *P < 0.05, ***P < 0.001, ****P < 0.0001, error bars are SEM.
Source data are available online for this figure.
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mutant did not act like phosphorylated MAP1S LC and bound to
microtubules in the microtubule co-sedimentation assay and COS-7
cells (Appendix Fig S5C and D). When MAP1S LC S786/812A was
overexpressed in neurons, microtubules formed loops at the tips of
the dendrites, possibly due to stabilization or continued growth
(Fig 6G). These data support that binding of MAP1S LC to micro-
tubules is directly regulated by CDKL5-dependent Ser786 and
Ser812 phosphorylation.
EB2 phosphorylation is lost in patient iPSC-derived neurons
In order to test whether the phosphorylation of novel substrates was
also altered in human subjects with CDD, we collected fibroblasts
from three patients: p.R59X, female; p.R59X, male; D135_F154del,
male and three controls. The R59X mutation leads to a premature
stop codon and loss of CDKL5 protein by nonsense mediated decay,
while D135_F154del leads to a truncated protein missing exon 7.
The fibroblasts were reprogrammed into iPSCs (Appendix Fig S6)
and then differentiated into neurons. We found that in patient-
derived neurons EB2 pS222 levels are reduced to 20% of control
phosphorylation level (Fig 7A and B). EB2 pS222 immunostaining
was also greatly reduced in patient-derived neuronal dendrites
(Fig 7C). These data show that novel CDKL5 substrates identified in
mice are conserved in humans and that the loss of CDKL5 in
humans promotes significant reductions in EB2 phosphorylation
levels.
In conclusion, in this study we report novel physiological CDKL5
substrates that are altered in neurons from CDD patients. Our
molecular and cellular analysis of CDKL5 and MAP1S function
suggests that MAP1S binding to microtubules causes longer plus-
end growth and less plus-end dynamics. Altered microtubule archi-
tecture in turn reduces efficient cargo trafficking (Fig 8).
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Figure 7. EB2 S223 phosphorylation is lost in CDD patient-derived neurons.
A, B Western blots for total EB2, pS223 and tubulin using protein lysates obtained from neurons derived from three patients with CDD and their related control.
1 = p.D135_F154del, male; 2 = p.R59X, male; 3 = p.R59X, female. Quantification of EB2 phosphorylation is normalized for total protein level. Student’s t-test: n = 3
patients/controls. *P < 0.05, error bars are SEM.
C Representative images of human iPSC-derived neurons co-stained with the neuronal dendrite marker MAP2, EB2 and EB2 pS223. EB2 phosphorylation is present in
dendrites of control neurons but not in CDD neurons. Enlarged images of the boxed areas are shown on the right panel. Scale bar is 20 lm.
Data information: human EB2 pS223 is mouse/rat EB2 pS222.
Source data are available online for this figure.
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Discussion
Novel CDKL5 substrates
Identifying CDKL5 substrates has been a major target in CDKL5 defi-
ciency disorder research in the last 10 years. Owing to the clinical
resemblance of CDD to Rett syndrome, initially methyl-CpG-binding
protein 2 (MECP2) was suggested to be a substrate (Mari et al,
2005). However, subsequent studies showed that MECP2 and DNA-
Methyl transferase 1, another putative substrate identified as a
CDKL5 binding partner (Kameshita et al, 2008), were weak in vitro
substrates (Lin et al, 2005; Sekiguchi et al, 2013). Amphiphysin-1, a
presynaptic protein, was identified in substrate screening using
wild-type CDKL5 to phosphorylate cellular protein fractions
(Sekiguchi et al, 2013). While AMPH1 Ser293 is an efficient in vitro
substrate that contains the RPXS* consensus (Katayama et al,
2015), CDKL5-dependent regulation of AMPH1 remains to be
demonstrated in vivo. Another study showed that Netrin G1 ligand
(NGL-1) Ser631 phosphorylation is mediated by CDKL5. However,
NGL-1 does not contain the RPXS* motif and it remains to be clari-
fied if it is a direct target of CDKL5, e.g. with in vitro kinase assays
(Ricciardi et al, 2012). The reduction in NGL-1 Ser631 phosphoryla-
tion in CDKL5 mutant cells is much less pronounced than the reduc-
tions in phosphorylation of EB2 and MAP1S shown here, suggesting
that NGL-1 may be indirectly affected. Recently, a phospho-antibody
array-based substrate screen reported histone deacetylase HDAC4
Ser632 as a putative CDKL5 phosphorylation site (Trazzi et al,
2016). Ser632 does not contain the CDKL5 consensus, and direct
confirmation of this phosphorylation site by in vitro kinase assays
remains to be done. The novel substrates we report here are direct
CDKL5 phosphorylation sites in vitro and MAP1S Ser812 and EB2
Ser222 are in vivo phosphorylation targets of CDKL5. Phosphoryla-
tion of these sites is not compensated by other kinases in the mouse
brain. Our study reports three bona fide CDKL5 substrates and high-
lights the use of AS-kinases in determining physiological substrates.
Phosphorylated RPXS* motif is present in more than 1,000
reported phosphorylation sites (phosphosite.org). Therefore, many
more CDKL5 substrates could be present and these remain to be
discovered and validated.
Cell type and subcellular localization of CDKL5 activity
Our results show that the vast majority of CDKL5 is found in pyra-
midal neurons. But incomplete reduction in EB2 pSer222 in condi-
tional knockouts when compared to full knockout mice indicates
that other cell type such as inhibitory neurons may also express low
levels of CDKL5 and phosphorylate its substrates. We did not find
any nuclear substrates of CDKL5, contrary to previous reports that
indicate its nuclear roles (Rusconi et al, 2008; Ricciardi et al, 2009).
CDKL5’s regulation by neuronal activity
CDKL5’s activity, as measured by phosphorylation of its substrates
EB2 and MAP1S, is higher at earlier postnatal stages and reflects an
early developmental role consistent with the early onset of CDD.
Behavioural analysis of full or conditional CDKL5 KO in excitatory
pyramidal neurons in cortex and hippocampus showed that CDKL5
activity is required for learning and memory (Wang et al, 2012;
Tang et al, 2017). Corroborating its relevance in adult plasticity,
CDKL5 substrate phosphorylations are present in adult, albeit at
lower levels. We found that NMDA receptor activation causes a
rapid reduction in EB2 pS222. It is possible that increased NMDA
receptor activation upon maturation of synapses in adult mice inhi-
bits baseline levels of EB2 phosphorylation. Our results also agree
with previous work showing that extrasynaptic NMDA receptor
stimulation negatively regulates CDKL5 levels in cultures (La
Montanara et al, 2015). NMDAR signalling, phosphatase activity
and developmental regulation of putative co-activators are among
possible factors that could reduce these phosphorylations in adult.
The reduction in CDKL5 phosphotargets with activity would be
predicted to reduce dynamic instability, consistent with the NMDA-
dependent loss of dynamic plus ends (Kapitein et al, 2011).
CDKL5 as a regulator of microtubule dynamics and trafficking
Several families of microtubule-associated proteins regulate micro-
tubule dynamics (Akhmanova & Steinmetz, 2015). Among these,
MAP1 family members MAP1A, MAP1B and MAP1S are cleaved to
form heavy and light chains, which can stabilize microtubules
(Halpain & Dehmelt, 2006). In this study, we showed that phosphory-
lation dissociates MAP1S from microtubules, similar to the
phosphoregulation of microtubule-binding protein Tau (Wang &
Mandelkow, 2016). We also presented evidence that CDKL5 KO
neurons have altered microtubule dynamics and this effect is rescued
upon reducing MAP1S levels by shRNA. These results indicate that
the more stable plus-end growth observed in CDKL5 KO neurons is
dependent on MAP1S levels. Our results agree with the findings in
HeLa cells where shRNA-mediated knockdown of MAP1S causes
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Figure 8. Summary schematic of novel CDKL5 substrates and functions
in microtubule dynamics.
CDKL5 phosphorylates microtubule-associated proteins EB2, MAP1S and
ARHGEF2 at their RPXS motifs. Double phosphorylation of the MAP1S LC
microtubule-binding region decreases MAP1S affinity for microtubules. Loss of
these MAP1S phosphorylations leads to impaired microtubule dynamic
instability in CDKL5 KO neurons. Altered microtubule stability in CDKL5 KO
neurons is also likely to be responsible for reduced cargo trafficking.
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shorter lived of EB3-EGFP comets (Tegha-Dunghu et al, 2014). In
addition, MAP1S shRNA reduces microtubule acetylation globally
indicating a reduction is stable microtubule population (Tegha-
Dunghu et al, 2014). In support of MAP1S’s role in microtubule stabil-
ity, MAP1S light chain overexpression in COS-7 cells leads to highly
stabilized microtubules, which are resistant to microtubule depoly-
merizing agents such as colchicine (Orban-Nemeth et al, 2005).
We investigated TrkB as a model cargo protein and found that its
anterograde run length is reduced in dendrites. This would indicate
that trafficking to distal dendritic regions could potentially be
affected in CDKL5 KO. Different cargo proteins may be affected dif-
ferently in CDKL5 KO animals, and additional experiments are
needed to determine the endogenous cargo proteins that may be
affected.
Despite its role in cytoskeletal and cargo transport regulation, we
did not find major differences in dendrite morphologies of CDKL5
KO mice in culture or in vivo. Our results are in agreement with
reports where subtle reductions in dendrite length were observed in
CDLK5-deficient pyramidal neurons from CDKL5 KO mice (Tang
et al, 2017; Zhou et al, 2017), but contrast with major dendritic
alterations (Amendola et al, 2014). Modest reductions in dendrite
arborization could be caused by compromised anterograde traf-
ficking in CDKL5 KO dendrites. Alterations in tubulin posttransla-
tional modifications could also affect selective molecular motor
types or microtubule orientation (Tas et al, 2017). The roles of
CDKL5 regulation of EB2 and ARHGEF2 remain to be studied to
achieving a comprehensive understanding of CDKL5’s influences on
cytoskeleton.
CDKL5 substrates in humans
EB2 pS222 antibody reliably reports CDKL5 activity in mice and in
humans. Neither CDKL5 KO mice nor CDD patients EB2 phosphory-
lation is compensated by other kinases, making EB2 Ser222 phos-
phorylation an ideal read-out for CDKL5 activity and a potential
molecular biomarker for pre-clinical or clinical studies. Our findings
reveal a novel signalling mechanism for activity-dependent micro-
tubule dynamics and cargo trafficking.
Materials and Methods
Animals
All mouse handling was performed according to the regulations of
the Animal (Scientific Procedures) Act 1986. Animal studies and
breeding were approved by the Francis Crick Institute ethical
committee and performed under U.K. Home Office project licence
(PPL 70/7771). Mice were housed in an animal facility of the Fran-
cis Crick Institute on an alternating 12-h light–dark cycle and
provided with water and food ad libitum. All mouse lines were
frequently backcrossed into C57BL/6J genetic background and
displayed normal health and weight. CDKL5 KO and cKO mice were
a kind gift from Cornelius Gross (Amendola et al, 2014). Heterozy-
gous females and wild-type males were used to maintain CDKL5 KO
mouse line. Brains were harvested at P4–50 of only male offspring
to ensure CDKL5 WT and hemizygous KO littermates. For analysis
of in vivo dendrite morphology at P20-50, Thy1-YFP or Thy1-GFP
expressing males were used for breeding with heterozygous CDKL5
females to introduce Thy1-YFP or Thy1-GFP transgene in the experi-
mental male offspring. Targeted CDKL5 deletion in excitatory
neurons was achieved by crossing homozygous floxed CDKL5
females with heterozygous Nex-Cre males. Brains were harvested at
P8 of CDKL5 hemizygous floxed males expressing Nex-Cre and Cre-
negative littermates as controls.
Cell cultures
HEK293T and COS-7 cells were maintained in Dulbecco’s modified
Eagle medium (Gibco) containing 10% foetal bovine serum
(Biosera) and penicillin/streptomycin at 37°C with 5% CO2. Both
lines had the species confirmed by Multiplex PCR. HEK293T was
authenticated by STR profiling. Sf9 insect cells were cultured in
suspension at 28°C in SF900 II serum-free medium (Invitrogen).
Mouse cortical and hippocampal neurons were cultured from
individual male E16.5 embryos from a heterozygous CDKL5 mother.
CDKL5+/Y or -/Y genotype of embryos was determined afterwards.
Neurons were plated at a density of 300,000 cells per 18 mm glass
coverslips (Fisher) or 1,000,000 cells per 35 mm glass-bottom dishes
(Mattek) coated with 60 lg/ml poly-D-lysine (Sigma) and 2.5 lg/ml
laminin (Sigma). Neurons were plated with minimal essential
medium (Gibco) containing 10% foetal bovine serum (Biosera),
0.5% dextrose, 0.11 mg/ml sodium pyruvate (Gibco) and 2 mM
glutamax (Gibco). After 4 h, cultures were transferred to neurobasal
medium (dye-free for glass-bottom dishes, Gibco) containing B27
(Gibco), 0.5 mM glutamax (Gibco), 12.5 lM glutamate, penicillin/
streptomycin and ciprofloxacin. 1/3rd of media was replaced with
fresh media every 3–4 days.
Generation of iPSCs
Skin biopsies from three subjects diagnosed with CDKL5 deficiency
disorder (CDD) and their first-degree sex-matched related control
(parent) were kindly donated through a collaboration with the
“International Foundation for CDKL5 Research” (p.R59X, female;
p.R59X, male; D135_F154del, male). The skin fibroblasts were
reprogrammed into iPSCs at the stem cell core at Sanford-Burnham
Medical Research Institute. Episomal vectors carrying the repro-
gramming factors OCT3/4, SOX2, KLF4, LIN28, L-MYC and p53
shRNA were used as previously described (Okita et al 2011). iPSC
colonies were cultured using mTeSR1 (Stem Cell Technologies) and
expanded into matrigel (BD Biosciences)-coated plates. Written
informed consent was obtained from all subjects, and this study
was approved by the UCSD Human Research Protection Program
Committee (IRB/ESCRO protocol #141223ZF).
Generation of human CDD neural cultures
Neural differentiation was performed as described elsewhere
(Thomas et al, 2017). Briefly, iPSC media was replaced with
DMEM/F12 (Corning Cellgro) with 1× HEPES, 1× penicillin-strepto-
mycin, 1× Glutamax (Life Technologies) and 1× N2 NeuroPlex
(Gemini Bio-products), supplemented with 1 mM dorsomorphin
(Tocris) and 10 mM SB431542 (StemGent). Next, colonies were kept
in suspension for 7 days to form embryoid bodies (EBs), which
were plated onto matrigel-coated plates and cultured using DMEM/
12 of 18 The EMBO Journal 37: e99763 | 2018 ª 2018 The Francis Crick Institute
The EMBO Journal CDKL5 as a microtubule regulator Lucas L Baltussen et al
F12 with 1× HEPES, 1× penicillin-streptomycin, Glutamax, 0.5× N2
NeuroPlex and 1× Gem21 NeuroPlex (Gemini Bio-products), supple-
mented with 20 ng/ml bFGF (Life Technologies). Neural rosettes
were manually collected, gently dissociated with accutase (Stem Cell
Technologies), and the neural progenitor cells (NPCs) were re-
plated on poly-L-ornithine/laminin-coated plates. Next, the NPCs
were differentiated into neurons by adding of 5 lM ROCK inhibitor
(Tocris) for 48 h and bFGF withdraw for 6 weeks.
DNA constructs and shRNAs
N-terminal FLAG-tagged full-length CDKL5 107 (NM_001323289.1)
in pcDNA3 was a kind gift from Charlotte Kilstrup-Nielsen at the
University of Insubria. Human CDKL51–352 was cloned into pRK5
mammalian expression vector with N-terminal HA-tag and pFastBac
HT insect cell expression vector with N-terminal His6-tag. CDKL5
kinase-dead K42A and analog-sensitive mutations F89A and C152A
were generated by site-directed mutagenesis. Mouse ARHGEF2
(NM_008487.3), mouse EB2 (NM_153058.4), rat MAP1S
(NM_001106070.1) full length and light chain (LC, 754–972 aa)
were cloned into pTriEx-6 (Novagen) to produce an N-terminal
Strep(II) fusion. Mouse EB2 and rat MAP1S LC were also cloned into
pRK5 mammalian expression vector with N-terminal HA-tag. Phos-
phomutant mutations ARHGEF2 S122A, EB2 S222A and MAP1S
S786A, S812A and S786/812A were generated by site-directed muta-
genesis. Phosphomimetic MAP1S LC S786/812D was generated by
site-directed mutagenesis. EB3-tdTomato was a gift from Erik Dent
(Addgene plasmid # 50708). TrkB-RFP was a kind gift from Erika
Holzbaur. All constructs were confirmed by DNA sequencing.
shRNA target sequences on MAP1S were 22 base pairs long and
selected via http://katahdin.cshl.org/: #1 50-ACCTCACTGTGTCCT
GTCCAAC-30 and #2 50-AGGCTTTACAGTGCTGGTGAAC-30. EB2
shRNA target sequence was 19 base pairs long (Komarova et al,
2005): 50-GATGAATGTTGATAAGGTA-30. Nineteen base pair scram-
bled shRNA target sequence was used as a control: 50-AGACCCAAG-
GATTAGAAGG-30. Hairpins targeting these sequences were cloned
in pLentiLox 3.7 which expresses EGFP via a separate promoter in
addition to expressing shRNA via a U6 promoter. Empty pLentiLox
3.7 vector was used as a cell fill to visualize neurons and referred to
as GFP. shRNA efficiency was validated by co-expressing 0.5 lg
HA-EB2 or HA-MAP1S LC with 1.5 lg corresponding shRNA in
HEK293T cells for 48 h using Xtremegene 9 (Roche) according to
manufacturer’s instructions. Protein levels were detected by anti-HA
antibody on Western blots.
Western blotting
Mouse cortices were solubilized directly in sample buffer containing
0.1 M DTT. Lysates were sonicated briefly three times and centri-
fuged at 20,000 g for 15 min. All protein samples were denatured at
95°C for 5 min and ran on NuPAGE 4–12% Bis–Tris polyacrylamide
gels (Invitrogen). Proteins transferred to Immobilon PVDF
membrane (Millipore) were blocked using 5% milk in TBST.
Primary antibodies incubated at 4°C o/n and HRP-conjugated
secondary antibodies (Jackson Immunoresearch) incubated at RT
for 2 h. Signal was detected using enhanced chemiluminescence
(Pierce). Quantification of Western blots was manually performed
using Fiji Gel Analyzer. Phosphorylations are measured relative to
the total protein level, except for the developmental expression,
where signals were normalized to tubulin. Intensities were normal-
ized to the highest average value depicted as 100%.
The following primary antibodies were used for Western blot-
ting: rat anti-HA (1:2,000, Roche 11 867 423 001), rabbit anti-thio-
phosphate ester (1:30,000, Abcam ab92570), rat anti-FLAG (1:2,000,
Thermo Scientific MA1-142), mouse anti-Strep(II) (1:1,000, IBA 2-
1507-001), mouse anti-aTubulin (1:50,000, Sigma T9026), rabbit
anti-CDKL5 (1:1,000, Abcam ab22453), rabbit anti-CDKL5 (1:1,000,
Sigma HPA002847), rat anti-EB2 (1:1,000, Abcam ab45767), rabbit
anti-MAP1S LC (1:1,000, Sigma HPA050934).
Phosphospecific antibodies
Rabbit polyclonal phosphospecific antibodies were raised against
the following phosphorylated (*) peptides by Covalab: TTRERPT-
S*AIY (mouse ARHGEF2 pS122), PGSTPSRPSS*AKRA (mouse EB2
pS222), RKAPARPSS*ASAT (mouse MAP1S pS786), AGDRNRPL-
S*ARSE (mouse MAP1S pS812). The peptide sequence for EB2
pS222 also matches 100% with rat and human sequences. Final
bleeds of immunized New Zealand White rabbits are purified with
affinity purification by Covalab: The immune serum is loaded
onto a column with the control peptide coupled to agarose beads,
thus retaining unmodified peptide-specific antibodies. The flow-
through is then loaded onto a column with the modified peptide
coupled to agarose beads, thus retaining the modified peptide-
specific antibodies. After elution, the eluate is assayed by ELISA
against both peptides to control its immunoreactivity and its
specificity against the modification. Phosphospecific antibodies
were used at the following dilutions: rabbit anti-ARHGEF2 pS122
(1:2,000), rabbit anti-EB2 pS222 (1:2,000), rabbit anti-MAP1S
pS786 (1:2,000), rabbit anti-MAP1S pS812 (overexpressed 1:2,000,
endogenous 1:500).
Protein purification
HA-CDKL51–352 and Strep(II)-ARHGEF2, Strep(II)-EB2 and Strep(II)-
MAP1S were overexpressed in HEK293T cells for 48 h using Xtreme-
gene 9 (Roche) according to manufacturer’s instructions. HA-tagged
and Strep(II)-tagged proteins were purified by anti-HA affinity
matrix (Roche) and Strep-tactin resin (IBA), respectively. Lysis
buffer contained 20 mM Tris–HCl pH 8.0, 150 mM NaCl, 1% NP-40,
10% glycerol, 1× protease inhibitor cocktail (Roche) and 1:100
phosphatase inhibitor cocktail III (Roche). Lysis was achieved by
incubation on ice for 30 min. Cells were pipetted up and down
several times before centrifugation at 20,000 g for 15 min at 4°C.
Supernatant containing solubilized HA-tagged proteins was
precleared using IgG-Sepharose (GE Healthcare) for 30 min at 4°C
and immunoprecipitated with HA affinity matrix for 2 h at 4°C.
Supernatant containing solubilized Strep(II)-tagged proteins was
purified at 4°C on columns with Strep-tactin resin. Proteins bound
on HA-matrix and Strep-tactin resin were washed three times.
HA-bound CDKL51–352 was washed an additional two times with
kinase buffer containing 20 mM Tris–HCl pH 7.5, 10 mM MgCl2, 1×
protease inhibitor cocktail (Roche) and 0.5 lM okadaic acid. Strep
(II)-tagged proteins were eluted by 50 mM desthiobiotin, and
protein concentration was measured by comparison to BSA
standards.
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His6-CDKL5
1–352 KD, His6-CDKL5
1–352 AS, Strep(II)-MAP1S LC
WT, Strep(II)-MAP1S LC S786/812A and Strep(II)-MAP1S LC S786/
812D were expressed and purified in insect cells. Typically, 1 l of
Sf9 insect cells at 2 × 106 cells/ml was infected with 2 ml of high
titre virus for 48 h and centrifuged at 3,000 g for 15 min at 4°C. Cell
pellets were resuspended in 25 mM NaHCO3 and lysed with 2× lysis
buffer containing 100 mM Tris–HCl pH 7.5, 1 M NaCl, 30 mM
imidazole pH 8.0, 5% glycerol, 10 mM MgSO4, 0.3% Triton X-100,
2 mM TCEP, 1× protease inhibitor cocktail (Roche) and 1:1,000
nuclease. Lysate was centrifuged at 55,000 g for 30 min at 4°C.
Supernatant containing solubilized His6-CDKL5
1–352 was loaded on
Hispur cobalt resin (Thermo Scientific) and washed three times with
wash buffer containing 50 mM Tris–HCl pH 7.5, 500 mM NaCl, 5%
glycerol, 1 mM TCEP, 0.01% Triton X-100 and 15 mM imidazole.
Bound proteins were eluted in 1 ml wash buffer containing 500 mM
imidazole. Protein concentration was measured by comparison with
BSA standards. Strep(II)-MAP1S LC WT, S786/812A and S786/812D
were purified similarly to the procedure described above using a
Strep-Tactin column.
In vitro kinase assays
Purified proteins were incubated with kinase buffer containing
20 mM Tris–HCl pH 7.5, 10 mM MgCl2, 1× protease inhibitor cock-
tail (Roche), 1 lM okadaic acid, 1 mM DTT, 100 lM ATP and
0.5 mM ATPcS or 6-benzyl-ATPcS (Biolog) at 30°C. Analog-sensi-
tive CDKL5 auto-thiophosphorylation was determined with ~250 ng
(200 nM) CDKL51–352 on HA-beads for 30 min. All substrate
thiophosphorylation was done with insect cell-purified AS-CDKL5,
6-benzyl-ATPcS and 150 ng (50 nM) MAP1S, 200 ng (170 nM) EB2,
150 ng (50 nM) ARHGEF2 or 300 ng (130 nM) AMPH1. Time
courses were performed with 50 ng (40 nM) AS-CDKL5 for
0–60 min. Titrations with 0–50 ng AS-CDKL5 incubated for 30 min
(MAP1S, EB2) or 60 min (AMPH1, ARHGEF2). Phosphomutant
experiments incubated as long as the titrations and contained
analog-sensitive and kinase-dead CDKL51–352 at the following
concentrations: 50 ng (AMPH1), 5 ng (MAP1S), 10 ng (EB2), 20 ng
(ARHGEF2). Reactions were quenched with 20 mM EDTA and
followed with alkylation by 5 mM p-nitrobenzyl mesylate (Abcam)
for 1 h at RT. Proteins were solubilized by sample buffer containing
0.1 M DTT. Thiophosphorylation was detected by anti-thiopho-
sphate ester antibody on Western blots.
Substrate labelling and covalent capture
Direct CDKL5 substrates were isolated by covalently capturing
thiophosphorylated peptides based on a method described before
(Hertz et al, 2010). Full P12 mouse brain was lysed in lysis buffer
containing 20 mM Tris–HCl pH7.5, 100 mM NaCl, 10 mM MgCl2,
0.5 mM DTT, 1× Protease Inhibitor Cocktail (Roche), 1 lM
okadaic acid and 0.25% IGEPAL NP-40. Lysates were sonicated
briefly three times and incubated for 30 min on ice. Lysates were
subsequently centrifuged at 20,000 g for 15 min at 4°C. Total
protein concentration was measured using BCA protein assay
(Pierce). 2.5 mg total protein P12 mouse brain lysate was labelled
by 3–5 lg AS or KD CDKL5 using a kinase labelling mix including
1 lM PKA inhibitor, 0.2 lM PKC inhibitor, 3 mM GTP, 100 lM ATP,
0.5 mM DTT, 0.5 lM okadaic acid and 0.5 mM 6-benzyl-ATPcS
for 1 h at 30°C on a nutator. Samples were denatured with 60%
urea and 10 mM TCEP for 1 h at 55°C. After dilution with
2× volume 50 mM ammonium bicarbonate while keeping TCEP at
10 mM, samples were digested by 30 lg Sequencing Grade Modi-
fied Trypsin (Promega) at pH 8.0 rotating o/n at 37°C. Trypsiniza-
tion was quenched by 0.5–1.0% trifluoroacetic acid. Clean-up of
the digested peptides is done with Sep-Pak Classic C18 Cartridges
(Waters) and completely dried on a Speedvac. Dried samples are
resuspended in 50% acetonitrile and 50 mM HEPES, set to pH 7.0
and incubated with Sulfolink Coupling Resin (Thermo Scientific)
and 25 lg BSA rotating o/n at RT. Resin was subsequently washed
with MQ, 5 M NaCl, 50% ACN and 5% formic acid, respectively,
then incubated with 10 mM DTT for 20 min, and eventually thio-
phosphorylated peptides were eluted with Oxone after 30 min of
incubation. Final pre-MS desalting and clean-up steps were done
with Zip Tips – P10, 0.6 ll C18 resin (Millipore), and purified
peptides were flash frozen in liquid N2 to be analysed with mass
spectrometry. Three independent experiments were performed
totalling 8 AS and 6 KD replicates. Exp. 1: 2 AS, 1 KD. Exp. 2:
2 AS, 2 KD. Exp. 3: 4 AS, 3 KD.
Mass spectrometry
Liquid chromatography-tandem mass spectrometry (LC-MS/MS)
was used to analyse direct thiophosphorylation of substrates by AS-
CDKL5. Each sample was resuspended in 1% TFA, sonicated for
15 min and injected 2 (Exp. 1 and 2) or 3 times (Exp. 3). Peptide
mixtures were separated on a 50 cm, 75 lm I.D. Pepmap column
over a 3-h gradient and eluted directly into the mass spectrometer
(Orbitrap Velos). Xcalibur software was used to control the data
acquisition. The instrument ran in data-dependent acquisition mode
with the top 10 most abundant peptides selected for MS/MS by CID,
MSA or HCD fragmentation techniques (one fragmentation tech-
nique per replicate).
Data processing was performed using the MaxQuant bioinfor-
matics suite, and protein database searching was done by the
Andromeda search engine using a Uniprot database of Mus
musculus proteins amended with common contaminants. A
protein, peptide and phosphosite estimated false discovery rate of
1% was used to generate tables with protein and phosphopeptide
identifications and quantifications, which featured matching
between runs for peptide identification. Phosphosite tables were
subsequently uploaded into the Perseus analysis program for
further statistical analysis and data visualization. The following
parameters were reported: peptide posterior error probabilities for
identification using a target-decoy approach. For sites found on
multiphosphorylated peptides, the least modified peptide ratio
was reported: phosphosite localization probabilities for site identi-
fication. Putative substrate candidates were considered when
repeated at least twice in AS samples and always absent in KD
controls, a PEP-score lower than 10E-05 and a localization proba-
bility higher than 0.800.
Immunocytochemistry
Cells were fixed with cold 4% PFA, 4% sucrose in PBS for 10–
15 min. For EB2 staining, neurons were fixed with methanol supple-
mented with 1 mM EGTA for 5 min at 20°C, followed by 5 min of
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4% PFA, 4% sucrose based on Jaworski et al Mouse neurons were
blocked and permeabilized with 0.2% Triton X-100/10% normal
goat serum in PBS for 60 min at RT. Human cells were treated the
same with 0.1% Triton X-100/3% BSA in PBS. In blocking buffer,
the following primary antibodies were incubated o/n at 4°C: mouse
anti-MAP2 (1:1,000, Sigma M9942), rat anti-EB2 (1:1,000, Abcam
ab45767), rabbit anti-EB2 pS222 (1:1,000), rabbit anti-MAP1S LC
(1:500, Sigma HPA050934), rabbit anti-OCT4 (1:500, Abcam
ab19857) and mouse anti-TRA-1-60 (1:250, Abcam ab16288). After
three 5-min washes with PBS, 1:500 secondary antibodies in PBS
were incubated for 2 h at RT and washed three times again with
one containing 1:2,000 DAPI stain (Thermo Scientific). Coverslips
were mounted with Fluoromount-G (Southern Biotech) or Prolong
Gold Antifade (Invitrogen) on glass slides.
Neuronal treatments
Neuronal depolarization was achieved by directly adding 3 M KCl
to a final concentration of 50 mM. 5 M NaCl to a final concentration
of 50 mM was used as a osmolarity control. Neurons were incu-
bated at 37°C for assay-dependent lengths of time and were lysed
directly in 1× sample buffer supplemented with 0.1 mM DTT. Zero-
minute controls were lysed without adding reagents. Thirty minutes
of pre-incubation with 100 lM D-AP5 (Abcam) was done before KCl
treatment to block NMDA receptors. NMDA and OA treatments
were performed similarly by either adding 100 mM NMDA to a final
concentration of 50 or 500 lM OA to a final concentration of 1 lM
directly to the culture media.
Neuronal morphology
Mice were put under surgical anaesthesia with 80–100 mg/kg keta-
mine (Vetalar) + 10 mg/kg xylazine (Rompun) injected intraperi-
toneally. While deeply anaesthetized, mice were fixed by cardiac
perfusion with ~0.5 ml/mg bodyweight PBS to clear the blood,
followed by ~1 ml/mg bodyweight 4% PFA until stiff. The brain
was removed and soaked in 4% PFA for 24 h. Fixed brains were cut
into 50- to 100-lm-thick coronal sections using Leica VT1000S
vibrating blade microtome and mounted on glass slides with Fluoro-
mount-G (Southern Biotech). Complete basal dendritic arbours of
Thy1-GFP labelled neurons were imaged without immunostaining
in 100-lm-thick coronal brain sections. Somatosensory layer 5 pyra-
midal cells were localized with help of the mouse brain atlas. Only
bright neurons in the middle of the cross-section were imaged to
prevent dendrites being cut. Z-stacks were acquired with a Leica
SP5-inverted confocal microscope and a Leica HyD photodetector
(20×/0.5 NA oil, 1.5× optical zoom, 1.5 lm z-step size, 2 airy
pinhole). Images were processed with Leica Application Suite and
Fiji. Basal dendritic arbours were reconstructed using Neurolucida
360 (MBF Bioscience) and analysed with Neurolucida Explorer
(MBF Bioscience). Three-dimensional total dendrite length was
calculated using Fiji plugin NLMorphologyViewer. For dendritic
spine analysis, basal secondary dendrites of Thy1-YFP labelled
neurons were imaged without immunostaining in 50-lm-thick coro-
nal brain sections. Somatosensory layer 5 pyramidal cells were
localized with help of the mouse brain atlas. Z-stacks were acquired
with a Leica SP5-inverted confocal microscope and a Leica HyD
photodetector (100×/1.46 NA oil, 2× optical zoom, 0.25 lm z-step
size, 1 airy pinhole). Images were processed with Leica Application
Suite and Fiji. Spine density and head diameter were manually
measured using a custom Fiji plugin.
Mouse primary neuronal cultures were transfected with 0.5 lg
GFP at DIV7 (dendrites) or DIV11 (spines) using Lipofectamine-
2000 (Invitrogen) according to manufacturer’s instructions. At
DIV11 (dendrites) or DIV18 (spines), neurons were fixed with 4%
PFA for 15 min at RT and permeabilized with 0.3% Triton X-100 in
10% normal goat serum. Primary antibodies incubated at 4°C o/n
and fluorescent secondary antibodies (Jackson Immunoresearch)
incubated at RT for 2 h. Cells were counterstained with DAPI
(Thermo Scientific) and mounted with Fluoromount-G (Southern
Biotech). The following antibodies were used for immunocytochem-
istry: rat anti-Ctip2 (1:2,000, Abcam), chicken anti-GFP (1:2,000,
Aves). Pyramidal neurons were identified by typical morphological
hallmarks like the presence of an axon and a branched dendritic
arbour. Hippocampal CA3 neurons were specifically selected by
negative Ctip2 staining. For dendrite morphology, images were
acquired with an Olympus IX83 widefield microscope and a Hama-
matsu ORCA-Flash4.0 camera in one focal plane (20×/0.75 NA air).
Images were processed in Olympus cellSens Dimension and Fiji.
Dendrites were reconstructed using Neurolucida 360 (MBF
Bioscience) and analysed with Neurolucida Explorer (MBF
Bioscience). For dendritic spine analysis, z-stacks of secondary
dendrites were acquired with a Leica SP5-inverted confocal micro-
scope and a Leica HyD photodetector (63×/1.4 NA oil, 4× optical
zoom, 1 lm z-step size, 1 airy pinhole). Images were processed with
Leica Application Suite and Fiji. Spine density was manually
measured using a custom Fiji plugin.
Microtubule dynamics
Live imaging of EB3-tdTomato expressing primary neurons at DIV14
was done at 37°C and 5% CO2 in 35-mm glass-bottom dishes
containing dye-free media. Thirty-six hours prior to imaging, mouse
primary cortical cultures were transfected with 1 lg EB3-tdTomato
and 1 lg shRNA-containing or empty pLL3.7-EGFP using Lipofec-
tamine-2000 (Invitrogen) according to manufacturer’s instructions.
Flat stretches of dendrite were selected based on their thickness and
protein expression levels. Three-minute videos were acquired at 1
frame/s with an Olympus IX81 spinning disc confocal microscope
and a Hamamatsu C9100-13 CCD camera in one focal plane (150×/
1.45 NA oil). Videos were processed using Volocity and Fiji. Back-
ground correction was applied by subtracting the average intensity.
Kymographs were generated using Fiji KymographClear 2.0 and
manually analysed.
TrkB trafficking
Live imaging of TrkB-RFP expressing primary neurons at DIV14
was done at 37°C and 5% CO2 in 35-mm glass-bottom dishes
containing dye-free media. Seventy-two hours prior to imaging,
mouse primary cortical cultures were transfected with 1 lg TrkB-
RFP and 1 lg pLL3.7-EGFP using Lipofectamine-2000 (Invitrogen)
according to manufacturer’s instructions. Flat stretches of dendrite
were selected based on their thickness and protein expression
levels. Two-minute videos were acquired at 3 frame/s with an
Olympus IX81 spinning disc confocal microscope and a
ª 2018 The Francis Crick Institute The EMBO Journal 37: e99763 | 2018 15 of 18
Lucas L Baltussen et al CDKL5 as a microtubule regulator The EMBO Journal
Hamamatsu C9100-13 CCD camera in one focal plane (150×/1.45
NA oil). Videos were processed using Volocity and Fiji. Bleach
correction was applied using a simple ratio correction method
with the background set at 1,400. Spots were manually tracked
with Fiji TrackMate and analysed with a custom Fiji plugin.
Tracks were considered dynamic when the net distance exceeded
5 lm. After intrapolation and track smoothing, retrograde and
anterograde runs were selected by instantaneous velocities
> 0.1 lm/s and a net distance > 2 lm without changing direction.
Kymographs were generated using Fiji KymographClear 2.0.
Microtubule colocalization
0.5 lg FLAG-CDKL5 and 0.5 lg HA-MAP1S LC were co-expressed in
COS7 cells for 36 h using Xtremegene 9 (Roche) according to manu-
facturer’s instructions. Coverslips were fixed with methanol for
5 min at 20°C and permeabilized with 0.3% Triton X-100 in 10%
normal goat serum. Primary antibodies incubated at 4°C o/n, and
fluorescent secondary antibodies (Jackson Immunoresearch) incu-
bated at RT for 2 h. Cells were counterstained with DAPI (Thermo
Scientific) and mounted with Fluoromount-G (Southern Biotech).
The following primary antibodies were used for immunocytochem-
istry: rat anti-FLAG (1:100, Thermo Scientific MA1-142), rabbit anti-
MAP1S LC (1:500, Sigma HPA050934), mouse anti-aTubulin
(1:1,000, Sigma T9026). High CDKL5-expressing cells were selected
for healthy nuclei and a distinct microtubule cytoskeleton.
Multichannel images were acquired with an Olympus IX83 widefield
microscope and a Hamamatsu ORCA-Flash4.0 camera in one focal
plane (60×/1.42 NA oil). Images were processed with Olympus cell-
Sens Dimension and Fiji. Colocalization of MAP1S and microtubules
was quantified binary (colocalization or no colocalization) manually
and by Pearson coefficient measured with HK means segmentation
and Colocalization Studio in Icy.
Microtubule co-sedimentation
Five microgram purified Strep(II)-MAP1S LC WT, S786/812A or
S786/812D was thiophosphorylated by 0.5 lg AS-CDKL51–352 with
0.5 mM benzyl-ATPyS in kinase buffer for 45 min at 30°C.
kinase-dead CDKL51–352 was used as a negative control. Co-sedi-
mentation of taxol-stabilized microtubules with thiophosphory-
lated MAP1S LC was based on a method described before
(Campbell & Slep, 2011). Taxol-stabilized microtubules were
prepared by incubating 20 lM purified tubulin protein (Cytoskele-
ton) with 1 mM GTP and DTT in BRB80 buffer, while gradually
increasing the taxol concentration to 20 lM at 37°C. 10 lM of
taxol-stabilized microtubules was incubated with 3 lM phosphory-
lated or non-phosphorylated MAP1S LC for 20 min at 25°C (3:1
ratio). 3 lM MTs with 3 lM MAP1S LC were used for the 1:1
ratio. 10% of the protein samples was saved as “input”, while
the rest was loaded on top of a 40% glycerol cushion in an ultra-
centrifuge tube and centrifuged at 100,000 g for 30 min at 25°C.
The supernatant was saved as the “soluble” fraction, and the
pellet as the “MT-bound” fraction after washing three times with
BRB80. Proteins were solubilized by sample buffer containing
0.1 M DTT. MAP1S LC binding to microtubules and phosphoryla-
tion state was detected by anti-MAP1S LC and phosphospecific
antibodies on Western blots.
Statistical analysis
Data were analysed using GraphPad Prism 7. Exact values of n and
statistical methods are mentioned in the figure legends. A P-value
lower than 0.05 was considered statistically significant. All error
bars in figures are SEM.
Data availability
The mass spectrometry proteomics data have been deposited to the
ProteomeXchange Consortium via the PRIDE (Vizcaino et al, 2016)
partner repository with the dataset identifier PXD010511 (https://
www.ebi.ac.uk/pride/archive/projects/PXD010511).
Expanded View for this article is available online.
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